Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
- Conditions
- Common Cold Associated With Cough
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2016-07-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 70
- Registration Number
- NCT02379637
Safety and Blood Donations in Adults Vaccinated With rMenB+OMV NZ.
- Conditions
- Meningitis, Meningococcal, Serogroup B
- Interventions
- Biological: Meningococcal (group B) multicomponent recombinant adsorbed vaccine
- First Posted Date
- 2014-12-02
- Last Posted Date
- 2016-01-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 55
- Registration Number
- NCT02305446
- Locations
- 🇵🇱
01, Novartis Investigational Site, Krakow, Poland
Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries
- Conditions
- Acute Blunt Soft Tissue Injuries/Contusions
- Interventions
- Drug: PlacebosDrug: placebo
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 215
- Registration Number
- NCT02290821
- Locations
- 🇺🇸
US Site, Houston, Texas, United States
A Within-subject Study to Evaluate the Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects Experiencing Delayed Onset Muscle Soreness
- First Posted Date
- 2014-10-22
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Novartis
- Target Recruit Count
- 102
- Registration Number
- NCT02271854
- Locations
- 🇺🇸
Lotus Clinical Research, 100 W California Blvd,, Pasadena,, California, United States
A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2)
- First Posted Date
- 2014-09-10
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1
- Registration Number
- NCT02235740
- Locations
- 🇺🇸
Novartis Investigative Site, Cary, North Carolina, United States
Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age
- Conditions
- Rabies Infection
- Interventions
- Biological: Rabies vaccineBiological: Rabies vaccines + Rabies immunoglobulins
- First Posted Date
- 2014-06-27
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 885
- Registration Number
- NCT02177032
- Locations
- 🇵🇭
4, De La Salle Health Sciences Institute, Cavite, Philippines
🇵🇭1, Research Institute for Tropical Medicine, Muntinlupa, Philippines
🇵🇭2, Asian Hospital and Medical Center, Muntinlupa, Philippines
Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.
- Conditions
- Meningococcal Disease
- Interventions
- Biological: rMenB+OMV
- First Posted Date
- 2014-05-19
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 239
- Registration Number
- NCT02141516
- Locations
- 🇮🇹
12, Novartis Investigational Site, Firenze, Italy
🇮🇹11, Novartis Investigational Site, Genova, Italy
🇮🇹10, Novartis Investigational Site, Milano, Italy
Antibody Levels Associated With Reduced Risk of Invasive Group B Streptococcus Disease in Infants Aged Less Than 90 Days
- Conditions
- Invasive Group B Streptococcus Disease
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2014-07-24
- Lead Sponsor
- Novartis
- Registration Number
- NCT02099149
- Locations
- 🇿🇦
Respiratory and Meningeal Pathogen Research Unit, Soweto, Gauteng, South Africa
Efficacy and Safety of Acetaminophen and Aspirin Versus Placebo in the Acute Treatment of Migraine
- Conditions
- Acute Migraine
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 900
- Registration Number
- NCT01973205
Efficacy and Safety of Diclofenac DDEA 2.32 % in Patient Suffering From Knee Osteoarthritis (OA)
- Conditions
- Osteoarthritis, Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-10-23
- Last Posted Date
- 2015-06-03
- Lead Sponsor
- Novartis
- Target Recruit Count
- 304
- Registration Number
- NCT01967550